Nu Skin Enterprises Reports Second-Quarter 2020 Results And Raises 2020 Guidance

Rhea-AI Summary

Nu Skin Enterprises reported Q2 2020 revenue of $612.4 million, a decline of 2% year-over-year, impacted by a 3% foreign exchange effect. Earnings per share for the quarter stood at $0.81, also down 2%. However, customer growth soared by 29%, indicating strong demand. The company raised its full-year revenue guidance to $2.37 to $2.45 billion, despite a forecasted 2-3% foreign currency impact. Digital sales accounted for over 85% of revenue, reflecting the effectiveness of their socially enabled business model.

Positive

• Raised 2020 revenue guidance to $2.37 to $2.45 billion.
• Customer growth increased by 29% in Q2 2020.
• Over 85% of revenue generated through digital transactions.
• Manufacturing division achieved 20% revenue growth.

Negative

• Revenue decreased by 2% compared to Q2 2019.
• Earnings per share declined from $0.83 to $0.81.
• Sales leader count dropped by 9%.

PROVO, Utah, Aug. 5, 2020 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced second-quarter results above expectations and raised its revenue and earnings per share guidance for 2020.

Executive Summary
Q2 2020 vs. Prior-Year Quarter
Revenue:	$612.4 million; (2%) •  (3%) fx impact or ($19.8) million
Earnings Per Share (EPS):	$0.81; (2%)
Sales Leaders:	56,036; (9%)
Customers:	1,499,900; +29%

"Our business performed well above expectations in the second quarter of 2020 driven by our socially enabled business model, strategic investments in technology and manufacturing, and our balanced product portfolio," said Ritch Wood, chief executive officer. "Strong global customer growth of 29 percent in the quarter, driven by our focus on empowering sales leaders to reach more customers, resulted in constant currency revenue growth due to the strength of our business in the Americas and Europe. Our Mainland China business continues to recover with slight sequential revenue improvement and strong customer growth.

"I am particularly proud of the way our global sales leaders have embraced socially enabled commerce, with more than 85 percent of revenue in the quarter coming through digital transactions. In addition, our manufacturing division generated 20 percent revenue growth and increased stability in our supply chain. In the first half, we generated strong cash from operations, raised our dividend, strengthened our balance sheet and reduced our outstanding shares by nearly eight percent."

Q2 2020 Year-Over-Year Operating Results
Revenue:	$612.4 million compared to $623.5 million •  (3%) fx impact or ($19.8) million
Gross Margin:	74.8% compared to 75.3% •  Nu Skin business was 77.6% compared to 77.8%
Selling Expenses:	40.6% compared to 39.4% •  Nu Skin business was 43.3% compared to 41.5%
G&A Expenses:	24.7% compared to 24.0%
Operating Margin:	9.5% compared to 11.9%
Other Income / (Expense):	$1.6 million compared to ($3.3) million
Income Tax Rate:	29.8% compared to 34.6%
EPS:	$0.81 compared to $0.83

 

Stockholder Value
Dividend Payments:	$19.4 million
Stock Repurchases:	$46.5 million •  $362.8 million remaining in authorization

 

Q3 and Full-Year 2020 Outlook
Q3 2020 Revenue:	$605 to $635 million; +3 to 8% •  Approximately (1 to 2%) fx impact
Q3 2020 EPS:	$0.78 to $0.88
2020 Revenue:	$2.37 to $2.45 billion; (2%) to +1% •  Approximately (2 to 3%) fx impact
2020 EPS	$2.85 to $3.10

"Our performance so far this year gives us confidence for the second half and momentum as we move into 2021. We believe the improved productivity of our sales leaders is driving strong customer growth and will lead to sales force expansion as we move toward the introduction of our ageLOC Boost device and Nutricentials Bioadaptive Skin Care in the second half. We will continue to focus on the expansion of our socially enabled business around the world with the release of our latest digital tool, Vera, a personal product recommendation app. Overall, we are confident in the direction of our strategy and the future ahead," Wood concluded.

Mark Lawrence, chief financial officer, added, "We delivered results above expectations and achieved constant currency revenue growth ahead of schedule. Given our performance in the first half and continued trends in our customer and sales leader pipeline, we are raising our guidance for the year. As we look ahead to the third quarter, we anticipate revenue of $605 to $635 million, which includes 1 to 2 percent unfavorable foreign currency impact, and earnings per share of $0.78 to $0.88. We are raising our 2020 revenue guidance to $2.37 to $2.45 billion, which reflects a negative foreign currency impact of 2 to 3 percent, and we anticipate annual earnings per share of $2.85 to $3.10."

Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available at the same URL through Aug. 19, 2020.

About Nu Skin Enterprises, Inc.
Founded more than 35 years ago, Nu Skin Enterprises, Inc. (NSE) empowers innovative companies to change the world with sustainable solutions, opportunities, technologies and life-improving values. The company currently focuses its efforts around innovative consumer products, product manufacturing and controlled environment agriculture technology. The NSE family of companies includes Nu Skin, which develops and distributes a comprehensive line of premium-quality beauty and wellness solutions through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific; and Rhyz, our strategic investment arm that includes a collection of sustainable manufacturing and technology innovation companies. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskinenterprises.com.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, product launches, customers and sales leaders, benefits to shareholders, strategies and initiatives; statements of management's expectations regarding the future status of the COVID-19 pandemic globally and across the company's markets, and government and public behavior in response to such status; projections regarding revenue, earnings per share, foreign currency fluctuations and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "continue," "anticipate," "project," "outlook," "guidance," "plan," "continue," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

• risk that epidemics, including the ongoing COVID-19 outbreak, and other crises could negatively impact our business;
• adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
• risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of fines, or any other adverse actions or events;
• any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
• political, legal, tax and regulatory uncertainties associated with operating in international markets, including Mainland China;
• uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
• risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
• uncertainties regarding the future financial performance of the businesses the company has acquired;
• risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
• regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;
• unpredictable economic conditions and events globally, including trade policies and tariffs;
• uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
• continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.

The following table sets forth revenue for the three-month periods ended June 30, 2020 and 2019 for each of our reportable segments (U.S. dollars in thousands):

	Three Months Ended June 30,									Constant- Currency
	2020			2019			Change			Change
Nu Skin
Mainland China	$	146,332		$	185,333			(21%)			(18%)
Americas/Pacific		127,919			92,841			38%			48%
South Korea		76,915			84,732			(9%)			(5%)
Southeast Asia		66,829			75,395			(11%)			(9%)
Japan		68,291			65,251			5%			2%
EMEA		50,776			43,400			17%			21%
Hong Kong/Taiwan		37,161			43,712			(15%)			(17%)
Other		(85)			1,249			(107%)			(107%)
Total Nu Skin		574,138			591,913			(3%)			—
Manufacturing		37,918			31,557			20%			20%
Grow Tech		310			30			933%			933%
Total	$	612,366		$	623,500			(2%)			1%

The following table sets forth revenue for the six-month periods ended June 30, 2020 and 2019 for each of our reportable segments (U.S. dollars in thousands):

	Six Months Ended June 30,									Constant- Currency
	2020			2019			Change			Change
Nu Skin
Mainland China	$	284,028		$	393,821			(28%)			(25%)
Americas/Pacific		202,492			179,297			13%			21%
South Korea		152,634			168,585			(9%)			(5%)
Southeast Asia		136,415			147,890			(8%)			(6%)
Japan		129,591			127,360			2%			—
EMEA		86,179			85,218			1%			4%
Hong Kong/Taiwan		72,988			84,270			(13%)			(15%)
Other		688			(177)			(489%)			(488%)
Total Nu Skin		1,065,015			1,186,264			(10%)			(7%)
Manufacturing		65,065			60,829			7%			7%
Grow Tech		314			30			947%			947%
Total	$	1,130,394		$	1,247,123			(9%)			(7%)

The company's Customers and Sales Leaders statistics by segment as of June 30, 2020 and 2019 are presented in the following table:

	As of June 30, 2020						As of June 30, 2019						% Increase (Decrease)
	Customers			Sales Leaders			Customers			Sales Leaders			Customers			Sales Leaders
Mainland China		321,946			17,104			226,877			24,336			42%			(30%)
Americas/Pacific		424,236			10,787			253,684			8,161			67%			32%
South Korea		159,926			6,881			180,365			7,239			(11%)			(5%)
Southeast Asia		155,822			6,790			137,450			7,417			13%			(8%)
Japan		125,332			6,011			127,900			5,931			(2%)			1%
EMEA		247,057			5,120			164,055			4,256			51%			20%
Hong Kong/Taiwan		65,581			3,343			70,089			4,223			(6%)			(21%)
Total		1,499,900			56,036			1,160,420			61,563			29%			(9%)

"Customers" are persons who purchased products directly from the company during the previous three months. Our Customer numbers do not include consumers who purchase products directly from members of our sales force.

"Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

 

NU SKIN ENTERPRISES, INC. Consolidated Statements of Income (Unaudited) (U.S. dollars in thousands, except per share amounts)
	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Revenue	$	612,366		$	623,500		$	1,130,394		$	1,247,123
Cost of sales		154,110			154,028			279,903			300,692
Gross profit		458,256			469,472			850,491			946,431
Operating expenses:
Selling expenses		248,628			245,828			454,670			495,536
General and administrative expenses		151,554			149,442			301,182			308,040
Total operating expenses		400,182			395,270			755,852			803,576
Operating income		58,074			74,202			94,639			142,855
Other income (expense), net		1,581			(3,326)			(4,593)			(6,174)
Income before provision for income taxes		59,655			70,876			90,046			136,681
Provision for income taxes		17,804			24,527			28,465			47,330
Net income	$	41,851		$	46,349		$	61,581		$	89,351
Net income per share:
Basic	$	0.81		$	0.83		$	1.15		$	1.61
Diluted	$	0.81		$	0.83		$	1.15		$	1.59
Weighted-average common shares outstanding (000s):
Basic		51,872			55,536			53,466			55,486
Diluted		51,925			55,943			53,502			56,030

 

NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited) (U.S. dollars in thousands)
	June 30, 2020			December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	375,512		$	335,630
Current investments		10,788			8,413
Accounts receivable, net		64,371			50,378
Inventories, net		261,969			275,891
Prepaid expenses and other		73,200			69,854
Total current assets		785,840			740,166
Property and equipment, net		444,848			453,604
Right-of-use assets		142,700			144,326
Goodwill		196,573			196,573
Other intangible assets, net		76,161			80,321
Other assets		148,371			154,016
Total assets	$	1,794,493		$	1,769,006
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	51,655		$	38,979
Accrued expenses		337,980			290,281
Current portion of long-term debt		95,000			27,500
Total current liabilities		484,635			356,760
Operating lease liabilities		103,043			105,701
Long-term debt		319,932			334,461
Other liabilities		94,871			96,795
Total liabilities		1,002,481			893,717
Stockholders' equity:
Class A common stock		91			91
Additional paid-in capital		563,115			557,544
Treasury stock, at cost		(1,427,064)			(1,324,826)
Accumulated other comprehensive loss		(93,441)			(85,292)
Retained earnings		1,749,311			1,727,772
Total stockholders' equity		792,012			875,289
Total liabilities and stockholders' equity	$	1,794,493		$	1,769,006

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-second-quarter-2020-results-and-raises-2020-guidance-301107000.html

SOURCE Nu Skin Enterprises, Inc.

FAQ

What are Nu Skin's Q2 2020 earnings and revenue results?

Nu Skin reported Q2 2020 earnings per share of $0.81 and revenue of $612.4 million, reflecting a 2% decline year-over-year.

How has Covid-19 affected Nu Skin's revenue guidance for 2020?

Nu Skin raised its revenue guidance for 2020 to between $2.37 and $2.45 billion, despite a negative foreign currency impact.

What significant growth did Nu Skin experience in Q2 2020?

Nu Skin saw a 29% increase in its customer base during Q2 2020.

How much of Nu Skin's revenue came from digital sales in Q2 2020?

More than 85% of Nu Skin's revenue in Q2 2020 was generated through digital transactions.

What is the forecast for Nu Skin's Q3 2020 revenue?

Nu Skin anticipates Q3 2020 revenue between $605 million and $635 million.